Sign in

You're signed outSign in or to get full access.

Aditya

Vice President and Equity Research Analyst at Goldman Sachs

Aditya is a Vice President and Equity Research Analyst at Goldman Sachs, specializing in the healthcare sector with a focus on biotechnology and pharmaceuticals. He covers key companies including Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Moderna, and BioNTech, boasting a strong performance track record with a 68% success rate on TipRanks and average return per rating of 12.5% over the past five years, ranking in the top 10% of analysts in his sector. Aditya joined Goldman Sachs in 2020 after previous roles at J.P. Morgan and Leerink Partners starting from 2015, and holds Series 7, 63, and 86 FINRA licenses along with an MBA from Wharton.

Aditya's questions to Virtu Financial (VIRT) leadership

Question · Q4 2025

Aditya asked about Virtu's top three strategic priorities for 2026, focusing on new initiatives or existing markets.

Answer

Co-President and Co-COO Joe Molluso stated that Virtu is not focusing on a small number of growth initiatives but rather on broad growth across the firm, dynamically responding to market opportunities. Key efforts include increasing the total firm's trading capital, investing in infrastructure, and acquiring excellent talent.

Ask follow-up questions

Fintool

Fintool can predict Virtu Financial logo VIRT's earnings beat/miss a week before the call